Articoli con mandati relativi all'accesso pubblico - Ramon TiuUlteriori informazioni
Non disponibili pubblicamente: 3
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
V Visconte, H Makishima, A Jankowska, H Szpurka, F Traina, A Jerez, ...
Leukemia 26 (3), 542-545, 2012
Mandati: US National Institutes of Health
Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis
J Huh, RV Tiu, LP Gondek, CL O'Keefe, M Jasek, H Makishima, ...
Genes, Chromosomes and Cancer 49 (4), 390-399, 2010
Mandati: US National Institutes of Health
Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis
A Tabarroki, DJ Lindner, V Visconte, L Zhang, HJ Rogers, Y Parker, ...
Leukemia 28 (7), 1486-1493, 2014
Mandati: US National Institutes of Health
Disponibili pubblicamente: 49
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
H Makishima, V Visconte, H Sakaguchi, AM Jankowska, S Abu Kar, ...
Blood, The Journal of the American Society of Hematology 119 (14), 3203-3210, 2012
Mandati: US National Institutes of Health
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
AM Jankowska, H Szpurka, RV Tiu, H Makishima, M Afable, J Huh, ...
Blood, The Journal of the American Society of Hematology 113 (25), 6403-6410, 2009
Mandati: US National Institutes of Health
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
AM Jankowska, H Makishima, RV Tiu, H Szpurka, Y Huang, F Traina, ...
Blood, The Journal of the American Society of Hematology 118 (14), 3932-3941, 2011
Mandati: US National Institutes of Health
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2 …
CN Harrison, N Schaap, AM Vannucchi, JJ Kiladjian, RV Tiu, P Zachee, ...
The Lancet Haematology 4 (7), e317-e324, 2017
Mandati: US National Institutes of Health
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
H Makishima, H Cazzolli, H Szpurka, A Dunbar, R Tiu, J Huh, ...
Journal of clinical oncology 27 (36), 6109-6116, 2009
Mandati: US National Institutes of Health
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
RV Tiu, LP Gondek, CL O'Keefe, P Elson, J Huh, A Mohamedali, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4552-4560, 2011
Mandati: US National Institutes of Health
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
SA Wang, RP Hasserjian, PS Fox, HJ Rogers, JT Geyer, ...
Blood, The Journal of the American Society of Hematology 123 (17), 2645-2651, 2014
Mandati: US National Institutes of Health
Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies
H Makishima, AM Jankowska, RV Tiu, H Szpurka, Y Sugimoto, Z Hu, ...
Leukemia 24 (10), 1799-1804, 2010
Mandati: US National Institutes of Health
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
V Visconte, HJ Rogers, J Singh, J Barnard, M Bupathi, F Traina, ...
Blood, The Journal of the American Society of Hematology 120 (16), 3173-3186, 2012
Mandati: US National Institutes of Health
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
MA Sekeres, RV Tiu, R Komrokji, J Lancet, AS Advani, M Afable, ...
Blood, The Journal of the American Society of Hematology 120 (25), 4945-4951, 2012
Mandati: US National Institutes of Health
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders
V Visconte, H Makishima, JP Maciejewski, RV Tiu
Leukemia 26 (12), 2447-2454, 2012
Mandati: US National Institutes of Health
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia
MG Afable, M Shaik, Y Sugimoto, P Elson, M Clemente, H Makishima, ...
Haematologica 96 (9), 1269, 2011
Mandati: US National Institutes of Health
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy
RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu, V Visconte, A Tabarroki, ...
Clinical cancer research 19 (4), 938-948, 2013
Mandati: US National Institutes of Health
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
N Daver, AE Perl, J Maly, M Levis, E Ritchie, M Litzow, J McCloskey, ...
Journal of Clinical Oncology 40 (35), 4048-4059, 2022
Mandati: US National Institutes of Health
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis
A Jerez, Y Sugimoto, H Makishima, A Verma, AM Jankowska, ...
Blood, The Journal of the American Society of Hematology 119 (25), 6109-6117, 2012
Mandati: US National Institutes of Health
SNP array–based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes
MG Afable, M Wlodarski, H Makishima, M Shaik, MA Sekeres, RV Tiu, ...
Blood, The Journal of the American Society of Hematology 117 (25), 6876-6884, 2011
Mandati: US National Institutes of Health
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited
A Jerez, LP Gondek, AM Jankowska, H Makishima, B Przychodzen, ...
Journal of clinical oncology 30 (12), 1343-1349, 2012
Mandati: US National Institutes of Health
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software